NNITS-Nitazoxanide for Norovirus in Transplant Patients Study

  • STATUS
    Recruiting
  • days left to enroll
    85
  • participants needed
    160
  • sponsor
    National Institute of Allergy and Infectious Diseases (NIAID)
Send
Updated on 24 February 2021
See if I qualify

Summary

This is a phase 2 multi-center, double-blind, placebo-controlled study of the efficacy and safety of nitazoxanide for the treatment of solid organ and hematopoietic stem cell transplant recipients with symptomatic diarrhea due to Norovirus. The study involves a total of 160 Hematopoietic Stem Cell or Solid Organ transplant recipients, equal to or greater than 12 years of age with diagnosis of Norovirus who will be selected and randomly assigned (1:1) to nitazoxanide or placebo group. The study duration is 60 months and subject participation duration is 6 months. Given the safety of prolonged therapy with nitazoxanide, lack of interactions with common post-transplant medications, putative antiviral activity and prolonged duration of viral shedding we are assessing 56 doses of therapy. The longitudinal monitoring phase will provide useful information on the course of host and viral responses in subjects with chronic Norovirus infection with and without treatment. Randomization will be stratified by age group (pediatric (12 through 17 years) vs. adult (greater than or equal to 18 years)), chronicity of Norovirus-associated symptoms (acute (less than 14 days) vs. chronic (greater than or equal to 14 days)) and transplant type (solid organ (SOT)) vs. hematopoietic stem cell transplant (HSCT)). Enrolled subjects will participate in 2 phases of the study: Treatment Phase, which will include dosing with the assigned study agent for 28 days. Longitudinal Monitoring Phase which will include telephone call on Days 35, 53, 113, 173. Primary objective is 1) to assess the clinical efficacy of nitazoxanide for the management of acute and chronic Norovirus in transplant recipients.

Description

This is a phase 2 multi-center, double-blind, placebo-controlled study of the efficacy and safety of nitazoxanide for the treatment of solid organ and hematopoietic stem cell transplant recipients with symptomatic diarrhea due to Norovirus. The study involves a total of 160 Hematopoietic Stem Cell or Solid Organ transplant recipients, equal to or greater than 12 years of age with diagnosis of Norovirus who will be selected and randomly assigned (1:1) into two treatment groups: nitazoxanide or placebo. The study duration is approximately 60 months and subject participation duration is approximately 6 months. Given the safety of prolonged therapy with nitazoxanide, lack of interactions with common post-transplant medications, putative antiviral activity and prolonged duration of viral shedding we are assessing 56 doses of therapy. The longitudinal monitoring phase will provide useful information on the course of host and viral responses in subjects with chronic Norovirus infection with and without treatment. Randomization will be stratified by age group (pediatric (12 through 17 years) vs. adult (greater than or equal to 18 years)), chronicity of Norovirus-associated symptoms (acute (less than 14 days) vs. chronic (greater than or equal to 14 days)) and transplant type (solid organ (SOT)) vs. hematopoietic stem cell transplant (HSCT)). Enrolled subjects will participate in 2 phases of the study: Treatment Phase, which will include dosing with the assigned study agent for 28 days. Longitudinal Monitoring Phase which will include telephone call on Days 35, 53, 113, 173. Primary objective is 1) to assess the clinical efficacy of nitazoxanide for the management of acute and chronic Norovirus in transplant recipients. Secondary Objectives are 1) to assess the virologic efficacy of nitazoxanide and 2) to assess the safety of nitazoxanide for the management of acute and chronic Norovirus in transplant recipients.

Details
Condition Gastroenteritis Norovirus
Treatment Placebo, Nitazoxanide
Clinical Study IdentifierNCT03395405
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Last Modified on24 February 2021

Eligibility

 Yes No Not Sure

Inclusion Criteria

Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Is your age between 12 yrs and 99 yrs?
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have any of these conditions: Do you have Gastroenteritis Norovirus??
Do you have Gastroenteritis Norovirus?
Gender: Male or Female
Subjects should meet all of the following inclusion criteria
Male or female age > / = 12 years
Recipient of a solid organ or hematopoietic stem cell transplant
Positive test result for Norovirus within 14 days of enrollment that is obtained as part of routine clinical care using a Norovirus testing available to the site
Active GI symptoms (diarrhea, or vomiting) that, in the opinion of the PI, are secondary to Norovirus. Patients must have active diarrhea, which is defined as at least 3 days of Bristol 6 or 7 stools in the past 2 weeks prior to enrollment per patient report
Willing and able to provide written informed consent and assent before initiation of any study procedures, consistent with local IRB policy
Subjects must be of non-childbearing potential or if of childbearing potential, must be using an effective method of birth control or must be abstinent
Non-childbearing potential is defined as surgically sterile or postmenopausal for > one year
Effective methods of birth control include the use of hormonal or barrier birth control such as implants, injectable contraceptives, combined oral contraceptives, intrauterine devices (IUDs),or condoms with spermicidal agents during study period. Female subjects must be using an effective method of birth control or practice abstinence and must agree to continue such precautions during the study and for 30 days after the Day 28 study visit
A woman is eligible if she is monogamous with a vasectomized male.This subject is considered low risk and not required to use contraception
Agrees to complete all screening requirements, study visits and procedures

Exclusion Criteria

Subjects meeting any of the exclusion criteria at baseline will be excluded
from study
participation
Other identified infectious causes of diarrhea at screening. Alternative diagnosis requiring treatment would be considered a co-infection; if the testing is positive for a pathogen that the PI does not feel is causing the symptoms, they may be included but the PI or his/her designee must document that the positive test is not clinically significant, does not require treatment and is not causing the symptoms making the patient eligible for enrollment
Any condition that would, in opinion of the Site Investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol
Subjects receiving oral or intravenous immunoglobulin therapy concurrently or in the 14 days prior to enrollment
Nitazoxanide use for any illness in the previous 30 days prior to randomization
Have received experimental products within 30 days prior to the study entry or plan to receive experimental products at any time during the study
Known sensitivity to nitazoxanide or any of the excipients comprising the nitazoxanide tablets
Subjects unable to swallow oral medications
Subjects with ostomy
Women who are pregnant or lactating or have a positive urine pregnancy test at screening/enrollment/Day 1
Clear my responses
Read more

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note